But ENPH stock is also fully priced for big growth, at 26-times forward earnings, which is pretty big for a solar stock. Enphase does appear to be in the early stages of expanding dollar share in a booming solar market. Going forward, ENPH stock is all about valuation versus growth. The result? Enphase reported blowout first-quarter 2019 numbers which comprised huge revenue growth, huge margin expansion, and a big full-year 2019 guide. Second, Enphase stock has steadily grown share in that rebounding market, transforming from a microinverter hardware provider to an ecosystem provider with solutions that comprise solar generation, storage, and management. This rebound in solar demand has provided a natural tailwind for ENPH stock. First, the solar industry has made a huge comeback in 2019, as lower prices, higher incentives, and better technology have created a surge in consumer and corporate solar energy demand. The big, 248% year-to-date rally in ENPH stock can be attributed to two things. Slotting in as the second-best-performing small-cap stock of 2019 is solar energy hardware provider Enphase Energy (NASDAQ: ENPH). ARQL is no exception: Just look at the stock chart over the past 18 months.Īs such, ARQL stock is an “invest with caution” situation at current elevated levels.
BEST PERFORMING MICRO CAP STOCKS FOR 2019 TRIAL
Gains from good clinical trial results for one product can be wiped out by bad clinical trial results for another product. But, small-cap bio-pharma stocks are notoriously volatile. The opportunity here in rare disease therapeutics is large. In response to the slew of favorable news, ARQL stock has nearly quadrupled in 2019. A few months later, in its Q1 report, ArQule reported favorable Phase 1 results for its key pipeline therapeutic, ARQ 531, in which it demonstrated substantial anti-tumor activity and a healthy safety profile. The company’s fourth-quarter earnings report, delivered in March, topped expectations by a wide margin. This is the exact formula ArQule followed in 2019, and it worked. The recipe for success for a small-cap bio-pharma stock is pretty simple: score a few favorable clinical trial results, and report a few favorable earnings reports. The top-performing small-cap stock from the Russell 2000 index so far this year is bio-pharmaceutical company ArQule (NASDAQ: ARQL).
Which small-cap stocks fall under this umbrella? And will they keep rallying into the end of the year? Let’s answer those questions by taking a closer look at those seven small-caps which have more than tripled in 2019. In other words, while small-cap stocks have largely trailed large-cap stocks in 2019, there have been a handful which have massively outperformed their large-cap peers. Even more jaw dropping, seven stocks in the index have more than tripled over the past six months.
In that index, 36 small-cap stocks have more than doubled so far. In the Russell 2000 index, there have been a handful of small-cap stocks that were huge winners in 2019. The Russell 2000 index is up just 13% year-to-date. Leading the rally? Tech stocks. The Nasdaq 100 index is up more than 20% year-to-date.
Year-to-date, the S&P 500 is up more than 17%, marking the biggest year-to-date gain for the index through June since 1997, when stocks were up 21% year-to-date. In fact, it has been the best year for stocks in over two decades.
0 kommentar(er)
